Do we have to treat subclinical rejections in early protocol renal allograft biopsies? 2007

J Masin-Spasovska, and G Spasovski, and S Dzikova, and G Petrusevska, and Lj Lekovski, and N Ivanovski, and Z Popov
Department of Nephrology, University Clinical Center, University of Skopje, Vodnjanska 17, 1000 Skopje, R. Macedonia.

The aim of the present study was to evaluate whether treatment of subclinical, borderline rejections (SR/BR) or histological findings of chronic allograft nephropathy (CAN) in protocol biopsies in the first month posttransplantation after living related kidney transplantation has a beneficial effect on graft histology and renal function at 6 months. Among the 40 paired biopsies, only 6/80 showed no histological lesions. BR was found in 13/40 and 12/40, and SR in 15/40 and 21/40 of patients on the 1- and 6-month biopsies, respectively. The mean histological index/total sum of scores for acute and chronic changes (HI) increased at 6-month biopsy: 5.3 +/- 2.9 vs 7.8 +/- 3.6 (P < .001). Similarly, the mean sum of histological markers for chronicity (CAN score) of 2.1 +/- 1.5 increased to 4.6 +/- 2.3 (P < .001) on the 6-month biopsy. When divided according to whether there was treatment of BR and SR, the treated BR/SR group on 1-month biopsy had a mean HI score of 7.11 +/- 1.9, which remained almost the same (7.11 +/- 2.32) at 6 months. Among the untreated BR/SR group it increased from 4.95 +/- 1.99 to 8.16 +/- 4.30. However, there was no difference in graft function between the groups from 1 to 6 months. In conclusion, a protocol 1-month biopsy may be valuable to establish the prevalence of BR/SR in stable allografts. The presence of an untreated BR/SR upon a 1-month biopsy showed greater susceptibility for histological deterioration on the 6-month biopsy due to an accelerated CAN process.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

J Masin-Spasovska, and G Spasovski, and S Dzikova, and G Petrusevska, and Lj Lekovski, and N Ivanovski, and Z Popov
March 2008, Nature clinical practice. Nephrology,
J Masin-Spasovska, and G Spasovski, and S Dzikova, and G Petrusevska, and Lj Lekovski, and N Ivanovski, and Z Popov
August 2004, Transplantation,
J Masin-Spasovska, and G Spasovski, and S Dzikova, and G Petrusevska, and Lj Lekovski, and N Ivanovski, and Z Popov
September 1999, Transplantation proceedings,
J Masin-Spasovska, and G Spasovski, and S Dzikova, and G Petrusevska, and Lj Lekovski, and N Ivanovski, and Z Popov
April 2008, Transplantation,
J Masin-Spasovska, and G Spasovski, and S Dzikova, and G Petrusevska, and Lj Lekovski, and N Ivanovski, and Z Popov
January 1997, Kidney international,
J Masin-Spasovska, and G Spasovski, and S Dzikova, and G Petrusevska, and Lj Lekovski, and N Ivanovski, and Z Popov
August 2005, Clinical transplantation,
J Masin-Spasovska, and G Spasovski, and S Dzikova, and G Petrusevska, and Lj Lekovski, and N Ivanovski, and Z Popov
November 2008, Vnitrni lekarstvi,
J Masin-Spasovska, and G Spasovski, and S Dzikova, and G Petrusevska, and Lj Lekovski, and N Ivanovski, and Z Popov
May 2000, Transplantation,
J Masin-Spasovska, and G Spasovski, and S Dzikova, and G Petrusevska, and Lj Lekovski, and N Ivanovski, and Z Popov
May 1991, Transplantation,
J Masin-Spasovska, and G Spasovski, and S Dzikova, and G Petrusevska, and Lj Lekovski, and N Ivanovski, and Z Popov
August 1978, Schweizerische medizinische Wochenschrift,
Copied contents to your clipboard!